您的当前位置:首页 > 行业数据 > 部分口服GLP-1/amylin类疗法与替尔泊肽疗效及安全性对比
图片属性
图片格式:PNG 图片大小:433KB 图片尺寸:2346*1129
同报告图片
 / 4
部分口服GLP-1/amylin类疗法与替尔泊肽疗效及安全性对比_第1页
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
部分口服GLP-1/amylin类疗法与替尔泊肽疗效及安全性对比_第2页
部分口服GLP-1/amylin类疗法与替尔泊肽疗效及安全性对比_第3页
部分口服GLP-1/amylin类疗法与替尔泊肽疗效及安全性对比_第4页
部分口服GLP-1/amylin类疗法与替尔泊肽疗效及安全性对比_第5页
所属报告: 【国金证券】医药行业研究:GLP-1专题,产品迭代驱动市场扩容,关注靶点、剂型及联合疗法研发进展-251117(38页).pdf
打包全文图表

相关数据

客服
商务合作
小程序
服务号
折叠